Lyell Immunopharma Reports Q3 2024 Financial Results
Company Announcements

Lyell Immunopharma Reports Q3 2024 Financial Results

Lyell Immunopharma, Inc. ( (LYEL) ) has released its Q3 earnings. Here is a breakdown of the information Lyell Immunopharma, Inc. presented to its investors.

Lyell Immunopharma, Inc., a Delaware-based clinical-stage cell therapy company, is focused on developing innovative T-cell therapies for treating solid tumors and hematologic malignancies. In its latest earnings report, Lyell Immunopharma revealed a continued focus on research and development, despite reporting a net loss of $151.1 million for the nine months ended September 30, 2024, compared to a $181.7 million loss in the same period in 2023. The company maintains a strong cash position with $100.3 million in cash and cash equivalents as of September 30, 2024. Key financial highlights include total operating expenses of $157.7 million and a net loss per common share of $0.59, reflecting ongoing investments in pipeline development and strategic collaborations. Looking ahead, Lyell Immunopharma’s management remains committed to advancing its pipeline and exploring market opportunities for its novel therapies, supported by a robust financial foundation and strategic partnerships.

Related Articles
TheFlyLyell Immunopharma reports Q3 net loss $44.6M vs. $50.9M last year
Jason CarrIs LYEL a Buy, Before Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App